Skip to main content

Kodiak Sciences Inc.

corporate_fare Company Profile

Kodiak Sciences Inc.

KOD·NASDAQ·Life Sciences·CIK 0001468748

Kodiak Sciences Inc. develops retinal medicines using its Antibody Biopolymer Conjugate ("ABC") platform, aiming to prevent and treat major causes of blindness. The company focuses on developing and commercializing next-generation therapeutics for various retinal diseases. Kodiak has three late-stage clinical programs. Its primary investigational medicine, tarcocimab tedromer ("Zenkuda" or "KSI-301"), is an anti-VEGF therapy based on the proprietary ABC platform. Zenkuda has a mean ocular half-life in humans of 20 days, which is approximately three times longer than approved anti-vascular endothelial growth factor ("VEGF") therapies. It is designed to maintain effective drug levels in ocular tissues for longer periods. Zenkuda is being developed as an intravitreal biologic monotherapy, intended to offer a flexible 1-month through 6-month dosing label for all patients with retinal vascular disease, including treatment-naïve, treatment-experienced, mild, and severe patients. Zenkuda has completed four Phase 3 pivotal studies: GLOW1 and GLOW2 for diabetic retinopathy ("DR"), BEACON for retinal vein occlusion ("RVO"), and DAYLIGHT for wet AMD. In the GLOW1 and GLOW2 studies, 100% of patients on extended 6-month dosing at Year 1 successfully treated DR and prevented disease progression. In the BEACON study, Zenkuda-treated patients were dosed at 8-week intervals during the first 6 months, and nearly half of Zenkuda patients did not require treatment in the second 6 months while achieving similar vision and anatomical outcomes as the aflibercept group at one year. The DAYLIGHT study showed non-inferior efficacy and compelling safety and tolerability for Zenkuda at a once-monthly dosing interval.

Kodiak Sciences Inc. (NASDAQ:KOD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for KOD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for KOD spans 8-K, 4, S-3ASR, 10-Q.

Recent high-impact activity:

  • Kodiak Q3 Loss Widens to $66.2M; $69M ATM Raise Extends Runway Into 2027
  • Q3 Loss Widens to $66.2M as Kodiak Raises $69M Through ATM Sales
  • Baker Bros. Buys $24.3M of Kodiak Sciences at $98.51, Adding to 20.4M-Share Stake
  • Kodiak Files New $350M At-The-Market Program With J.P. Morgan
  • Baker Bros. Adds $58.6M Kodiak Sciences Stake After Phase 3 Win

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$229.97M
Diluted EPS
-$4.32
Op. Cash Flow
-$136.01M
Free Cash Flow
-$136.51M
Operating Income
-$234.39M
Cash & Equivalents
$209.86M
Debt / Equity
0.00×
Shares Outstanding
61.76M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-134887

Short Interest & Short Volume

9.34 days to cover

FINRA reported short interest of 8,115,058 shares in KOD as of the October 30, 2026 settlement, a 4.5% decrease from the prior period — about 9.3 days to cover at its recent average daily volume. On November 20, 2026, 58.5% of KOD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,115,058 shares as of October 30, 2026
Change vs prior period▼ 4.5%
Days to cover9.34 at avg daily volume of 868,920
Daily short volume (FINRA facilities)58.5% of 221,113 shares on November 20, 2026
5-day average short volume57.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for KOD, detected from its recent SEC filings · based on capital-structure filings through 2026-10-20.

ATM program1 shelf registration

New $350M ATM Program Established · Dilution If Fully Drawn

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with K →
$97.26 +0.09% today
52-week range · as of 2026-11-12 $18.05 – $112.31
Market cap
$6.35B
Volume
693.1K (0.7× avg)
3-mo avg 956.2K
Live data · 2026-11-22 07:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KOD - Latest Insights

KOD
Nov 12, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $108.12
Real-time Price: $97.26 info
Change: -$10.86 (-10%) info
Market Cap: $6.354B info
KOD
Nov 12, 2026, 4:00 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $108.25
Real-time Price: $97.26 info
Change: -$10.99 (-10%) info
Market Cap: $6.354B info
KOD
Nov 06, 2026, 4:55 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $99.30
Real-time Price: $97.26 info
Change: -$2.04 (-2%) info
Market Cap: $6.354B info
KOD
Oct 20, 2026, 5:19 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $92.97
Real-time Price: $97.26 info
Change: +$4.29 (+5%) info
Market Cap: $6.354B info
KOD
Sep 30, 2026, 4:29 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $94.50
Real-time Price: $97.26 info
Change: +$2.76 (+3%) info
Market Cap: $6.354B info
KOD
Sep 28, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $60.69
Real-time Price: $97.26 info
Change: +$36.57 (+60%) info
Market Cap: $6.354B info
KOD
Sep 28, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $51.98
Real-time Price: $97.26 info
Change: +$45.28 (+87%) info
Market Cap: $6.354B info
KOD
Sep 28, 2026, 6:35 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $43.78
Real-time Price: $97.26 info
Change: +$53.48 (+122%) info
Market Cap: $6.354B info
KOD
Sep 25, 2026, 6:22 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $38.06
Real-time Price: $97.26 info
Change: +$59.20 (+156%) info
Market Cap: $6.354B info
KOD
Aug 13, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $40.90
Real-time Price: $97.26 info
Change: +$56.36 (+138%) info
Market Cap: $6.354B info
KOD
Aug 13, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.14
Real-time Price: $97.26 info
Change: +$57.12 (+142%) info
Market Cap: $6.354B info
KOD
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $43.68
Real-time Price: $97.26 info
Change: +$53.58 (+123%) info
Market Cap: $6.354B info
KOD
May 07, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $43.68
Real-time Price: $97.26 info
Change: +$53.58 (+123%) info
Market Cap: $6.354B info
KOD
May 07, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $43.77
Real-time Price: $97.26 info
Change: +$53.49 (+122%) info
Market Cap: $6.354B info
KOD
Mar 31, 2026, 5:02 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $38.40
Real-time Price: $97.26 info
Change: +$58.86 (+153%) info
Market Cap: $6.354B info
KOD
Mar 31, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $39.00
Real-time Price: $97.26 info
Change: +$58.26 (+149%) info
Market Cap: $6.354B info
KOD
Mar 31, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $38.60
Real-time Price: $97.26 info
Change: +$58.66 (+152%) info
Market Cap: $6.354B info
KOD
Mar 26, 2026, 9:56 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.45
Real-time Price: $97.26 info
Change: +$57.81 (+147%) info
Market Cap: $6.354B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets